KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 151–167 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12D3
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	—	accepted	EID2251 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2252 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 16497971 · Hoang et al., 2006 · Open in CIViC	civic
Akt Inhibitor MK2206	Pancreatic Carcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID937 Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximatel… (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC	civic
KRAS G12C4
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2261 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	—	accepted	EID2262 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted
KRAS G12S3
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2277 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2278 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted
KRAS RS617643701
Carboplatin + PaclitaxelSubstitutes	Ovarian CarcinomaALIAS	Predictive	B	Supports Resistance	3	accepted	EID664 The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EO… (full text at CIViC) PMID 22139083 · Ratner et al., 2012 · Open in CIViC	civic
KRAS G12/G132
Gemcitabine + TrametinibCombination	Pancreatic Adenocarcinoma	Predictive	B	Supports Resistance	4	accepted	EID622 Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastati… (full text at CIViC) PMID 24915778 · Infante et al., 2014 · Open in CIViC	civic
Trametinib	Pancreatic Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID990 KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or pla… (full text at CIViC) PMID 24915778 · Infante et al., 2014 · Open in CIViC	civic
KRAS Mutation1
PI3Kbeta Inhibitor AZD8186 + SCH772984Combination	Pancreatic Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID1003 Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either ag… (full text at CIViC) PMID 26725216 · Hayes et al., 2016 · Open in CIViC	civic
KRAS Exon 2 Mutation1
Erlotinib	Pancreatic Carcinoma	Predictive	B	Does Not Support Resistance	3	accepted	EID916 KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment. PMID 23435671 · Boeck et al., 2013 · Open in CIViC	civic
NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7492 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic
NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7493 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old … (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Gemcitabine	US FDA	Malignant Breast Neoplasm	in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.	approved	Aug 4, 2011	openfda
Gemcitabine	US FDA	Malignant Ovarian Neoplasm	in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.	approved	Aug 4, 2011	openfda
Irinotecan	CA Health Canada	—	Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02528800) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 12, 2024

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,652)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 798 recruiting · 366 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 151–200 of 1,652 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05681780	Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC	recruiting	Phase 1	20	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Sep 16, 2026	clinicaltrials
NCT05786924	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies	recruiting	Phase 1 / Phase 2	554	Institut de Recherches Internationales ServierOTHER	10	Sep 16, 2026	clinicaltrials
NCT06233942	Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors	recruiting	Phase 1	308	BeOne MedicinesINDUSTRY	5	Sep 16, 2026	clinicaltrials
NCT06311851	Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases	active not recruiting	Phase 1 / Phase 2	40	Pardis Noor Medical Imaging and Cancer CenterOTHER	1	Sep 16, 2026	clinicaltrials
NCT06366347	ALPINE: Maintenance Letrozole/Abemaciclib	recruiting	Phase 2	32	Dana-Farber Cancer InstituteOTHER	1	Sep 16, 2026	clinicaltrials
NCT06427941	A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors	recruiting	Phase 1 / Phase 2	630	BeOne MedicinesINDUSTRY	9	Sep 16, 2026	clinicaltrials
NCT06497556	A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer(Krascendo 1)	active not recruiting	Phase 3	338	Hoffmann-La RocheINDUSTRY	26	Sep 16, 2026	clinicaltrials
NCT07492680	A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)	recruiting	Phase 2	260	Bristol-Myers SquibbINDUSTRY	13	Sep 16, 2026	clinicaltrials
NCT07680764	A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	recruiting	Phase 2	160	Bristol-Myers SquibbINDUSTRY	12	Sep 16, 2026	clinicaltrials
NCT07748208	A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes	not yet recruiting	Phase 2	40	Hoffmann-La RocheINDUSTRY	0	Sep 16, 2026	clinicaltrials
NCT07822542	A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer	not yet recruiting	Phase 3	448	Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY	0	Sep 16, 2026	clinicaltrials
NCT07823348	JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer	not yet recruiting	Phase 3	560	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	Sep 16, 2026	clinicaltrials
NCT02196181	Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread	active not recruiting	Phase 2	280	National Cancer Institute (NCI)NIH	1	Sep 15, 2026	clinicaltrials
NCT03004287	2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy	active not recruiting	Phase 2	50	University of ArkansasOTHER	1	Sep 15, 2026	clinicaltrials
NCT04462406	Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	active not recruiting	Phase 2	150	ECOG-ACRIN Cancer Research GroupNETWORK	1	Sep 15, 2026	clinicaltrials
NCT04511013	A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases	recruiting	Phase 2	112	SWOG Cancer Research NetworkNETWORK	1	Sep 15, 2026	clinicaltrials
NCT05438459	GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites	recruiting	Phase 1 / Phase 2	176	Kyushu UniversityOTHER	1	Sep 15, 2026	clinicaltrials
NCT05739981	Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer(MRD)	recruiting	Phase 1 / Phase 2	30	ImunonINDUSTRY	1	Sep 15, 2026	clinicaltrials
NCT05854498	Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	recruiting	Phase 2	50	University of Wisconsin, MadisonOTHER	1	Sep 15, 2026	clinicaltrials
NCT06806852	A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone	active not recruiting	Phase 1	91	Boehringer IngelheimINDUSTRY	22	Sep 15, 2026	clinicaltrials
NCT06899126	Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer(DESTINY-Lung06)	recruiting	Phase 3	686	Daiichi SankyoINDUSTRY	23	Sep 15, 2026	clinicaltrials
NCT06915025	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer(OVATION-3)	recruiting	Phase 3	500	ImunonINDUSTRY	1	Sep 15, 2026	clinicaltrials
NCT07044362	Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis	recruiting	N/A	100	Case Comprehensive Cancer CenterOTHER	1	Sep 15, 2026	clinicaltrials
NCT07819604	Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer	not yet recruiting	Phase 2	85	Xijing HospitalOTHER	0	Sep 15, 2026	clinicaltrials
NCT02734537	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery	recruiting	Phase 2	189	ECOG-ACRIN Cancer Research GroupNETWORK	1	Sep 14, 2026	clinicaltrials
NCT03149029	Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma	active not recruiting	Phase 2	16	Massachusetts General HospitalOTHER	1	Sep 14, 2026	clinicaltrials
NCT04013542	Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	active not recruiting	Phase 1	21	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT04140526	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001)	active not recruiting	Phase 1 / Phase 2	733	OncoC4, Inc.INDUSTRY	2	Sep 14, 2026	clinicaltrials
NCT04380545	Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer	recruiting	Phase 1 / Phase 2	15	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT04575935	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial	recruiting	Phase 3	580	M.D. Anderson Cancer CenterOTHER	5	Sep 14, 2026	clinicaltrials
NCT04721132	Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer	active not recruiting	Phase 2	16	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT04858009	Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis	recruiting	Phase 2	40	Mayo ClinicOTHER	1	Sep 14, 2026	clinicaltrials
NCT05067283	A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)(KANDLELIT-001)	recruiting	Phase 1	830	Merck Sharp & Dohme LLCINDUSTRY	21	Sep 14, 2026	clinicaltrials
NCT05482516	Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI)	recruiting	Phase 3	20	Georgetown UniversityOTHER	1	Sep 14, 2026	clinicaltrials
NCT05721755	Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck	active not recruiting	Phase 3	290	ECOG-ACRIN Cancer Research GroupNETWORK	1	Sep 14, 2026	clinicaltrials
NCT06101134	A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations	active not recruiting	Phase 2	100	Bristol-Myers SquibbINDUSTRY	5	Sep 14, 2026	clinicaltrials
NCT06236438	Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(LIVIGNO-4)	recruiting	Phase 2 / Phase 3	840	AbbVieINDUSTRY	12	Sep 14, 2026	clinicaltrials
NCT06596473	A Study of BG-C477 in Participants With Advanced Solid Tumors	recruiting	Phase 1	310	BeOne MedicinesINDUSTRY	8	Sep 14, 2026	clinicaltrials
NCT06787612	Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer	recruiting	Phase 2	297	Regeneron PharmaceuticalsINDUSTRY	5	Sep 14, 2026	clinicaltrials
NCT07491445	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(RASolute 303)	recruiting	Phase 3	900	Revolution Medicines, Inc.INDUSTRY	10	Sep 14, 2026	clinicaltrials
NCT01585805	Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	active not recruiting	Phase 2	83	National Cancer Institute (NCI)NIH	3	Sep 11, 2026	clinicaltrials
NCT03147287	Palbociclib After CDK and Endocrine Therapy (PACE)	active not recruiting	Phase 2	220	Dana-Farber Cancer InstituteOTHER	1	Sep 11, 2026	clinicaltrials
NCT04191499	A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(INAVO120)	active not recruiting	Phase 2 / Phase 3	325	Hoffmann-La RocheINDUSTRY	28	Sep 11, 2026	clinicaltrials
NCT04410796	Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers	recruiting	Phase 2	571	Memorial Sloan Kettering Cancer CenterOTHER	1	Sep 11, 2026	clinicaltrials
NCT04485013	TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	active not recruiting	Phase 1	240	Tizona Therapeutics, IncINDUSTRY	1	Sep 11, 2026	clinicaltrials
NCT04929223	A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	recruiting	Phase 1	542	Hoffmann-La RocheINDUSTRY	11	Sep 11, 2026	clinicaltrials
NCT05186974	Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)(EVOKE-02)	active not recruiting	Phase 2	193	Gilead SciencesINDUSTRY	12	Sep 11, 2026	clinicaltrials
NCT05365581	A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer	recruiting	Phase 1	398	Astellas Pharma Global Development, Inc.INDUSTRY	8	Sep 11, 2026	clinicaltrials
NCT05845450	Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)	recruiting	Phase 2	197	Gruppo Oncologico del Nord-OvestOTHER	1	Sep 11, 2026	clinicaltrials
NCT05985954	Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy	recruiting	Phase 1	27	M.D. Anderson Cancer CenterOTHER	1	Sep 11, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,652)

Linked publications (113)